Related references
Note: Only part of the references are listed.IL-6 inhibitors for treatment of rheumatoid arthritis: past, present, and future
Go Woon Kim et al.
ARCHIVES OF PHARMACAL RESEARCH (2015)
Effects of blood processing and sample storage on the stability of biotherapeutics and anti-drug antibodies
Matthew Andisik et al.
BIOANALYSIS (2015)
A Tutorial on Target-Mediated Drug Disposition (TMDD) Models
P. Dua et al.
CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY (2015)
Interleukin 6 and Rheumatoid Arthritis
Yuji Yoshida et al.
BIOMED RESEARCH INTERNATIONAL (2014)
Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial
Cem Gabay et al.
LANCET (2013)
IL-6/IL-6 receptor system and its role in physiological and pathological conditions
Masahiko Mihara et al.
CLINICAL SCIENCE (2012)
Selection between Michaelis-Menten and target-mediated drug disposition pharmacokinetic models
Xiaoyu Yan et al.
JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS (2010)
Therapeutic targets in rheumatoid arthritis: the interleukin-6 receptor
Jean-Michel Dayer et al.
RHEUMATOLOGY (2010)
Share Paper
